Calliditas Therapeutics AB (Calliditas Therapeutics AB) Long-Term Capital Lease Obligation : $2.64 Mil (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Long-Term Capital Lease Obligation?

Calliditas Therapeutics AB's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $2.64 Mil.

Calliditas Therapeutics AB's quarterly Long-Term Capital Lease Obligation increased from Jun. 2023 ($1.91 Mil) to Sep. 2023 ($2.65 Mil) but then declined from Sep. 2023 ($2.65 Mil) to Dec. 2023 ($2.64 Mil).

Calliditas Therapeutics AB's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($2.65 Mil) to Dec. 2022 ($1.52 Mil) but then increased from Dec. 2022 ($1.52 Mil) to Dec. 2023 ($2.64 Mil).

Calliditas Therapeutics AB Long-Term Capital Lease Obligation Historical Data

The historical data trend for Calliditas Therapeutics AB's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Long-Term Capital Lease Obligation Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.11

2.65

1.52

2.64

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															1.76	1.52	1.91	2.65	2.64

Calliditas Therapeutics AB (NAS:CALT) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Calliditas Therapeutics AB Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.